Showing 7171-7180 of 8467 results for "".
- Industry Vet Curtis Cluff Named President and CFO of BioPhotas Inc.https://practicaldermatology.com/news/industry-vet-curtis-cluff-named-president-and-cfo-of-biophotas-inc/2461378/Curtis Cluff is the new President and Chief Financial Officer BioPhotas Inc., manufacturers of the Celluma series of light therapy devices. In this newly created role, Mr. Cluff will report to Patrick Johnson, Chief Executive Officer and inventor of the Celluma. &quo
- Octagam 10% Performs Well in Adults with Dermatomyositishttps://practicaldermatology.com/news/octagam-10-performs-well-in-adults-with-dermatomyositis/2461376/Octapharma’s Octagam 10% [Immune Globulin Intravenous (Human)] is efficacious and well-tolerated in adults with dermatomyositis, ac
- National Physician Assistant Week Celebrates Work of PAshttps://practicaldermatology.com/news/national-physician-assistant-week-celebrates-work-of-pas/2461373/The American Academy of Physician Associates (AAPA) is celebrating National Physician Assistant Week October 6-12 to recognize the PA profession and its contributions to the nation’s health. This PA Week, the AAPA wants to spread the word: PAs Go Beyond! Do you know a PA who goes beyond? Th
- Business News: Incyte Buys Startup Villarishttps://practicaldermatology.com/news/business-news-incyte-buys-startup-villaris/2461370/Incyte will pay $70 million upfront to buy Villaris Therapeutics, a startup working on an experimental drug for vitiligo. Villaris’ lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023. Villaris&
- New Research: Ticks Weaken Skin's Immune Responsehttps://practicaldermatology.com/news/new-research-ticks-weaken-skins-immune-response/2461364/Tick saliva inhibits the skin's defense function, thereby increasing the risk of diseases such as tick-borne encephalitis (TBE) or Lyme disease, according to new research in the Journal of Clinical Investigation. The re
- FDA Clears CellFX System for the Treatment of SHhttps://practicaldermatology.com/news/fda-clears-cellfx-system-for-the-treatment-of-sh/2461358/The U.S. Food and Drug Administration (FDA) granted Pulse Bioscience’s CellFX System (FDA) 510(k)marketing clearance for the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-II. This specific indication clearance enhances the CellFX
- Investigational Cannabinoid Receptor Agonist Proves Safe and Effective in Amyopathic Dermatomyositishttps://practicaldermatology.com/news/investigational-cannabinoid-receptor-agonist-proves-safe-and-effective-in-amyopathic-dermatomyositis/2461357/Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis, a new study in the Journal of Investigative Dermatology suggests. This phase 2 trial, the
- Meet EMFACE From BTLhttps://practicaldermatology.com/news/meet-emface-from-btl/2461350/BTL is taking on the minimally invasive facial aesthetic category with the launch of EMFACE. Emface simultaneously emits both
- Positive Dupixent Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe ADhttps://practicaldermatology.com/news/positive-dupixent-phase-3-data-in-children-aged-6-months-to-5-years-with-moderate-to-severe-ad/2461349/Dupixent significantly improved skin clearance, and reduced itch and overall disease severity in children as young as 6 months old, according to a new Phase 3 trial in the Lancet. Thes
- Midmark Gives Back: Trade-in Program Results in Nearly 1,000 Exam Tables Donated to World Visionhttps://practicaldermatology.com/news/midmark-gives-back-trade-in-program-results-in-nearly-1000-exam-tables-donated-to-world-vision/2461347/Midmark Corp.'s 2021 trade-in program collected 1,000 eligible exam tables. The tables were donated primarily to World Vision, where they are refurbished and delivered to clinics that provide health c